Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
THMO

THMO - ThermoGenesis Holdings Inc Stock Price, Fair Value and News

00
Market Closed

4/100

THMO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

THMO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

000

THMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

THMO Price Action

THMO RSI Chart

THMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

THMO Valuation

THMO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

000

THMO Fundamentals

THMO Revenue

THMO Earnings

THMO Profitability

THMO Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.6M000
202310.4M9.6M9.7M9.4M
202210.4M11.3M10.2M10.5M
20218.1M8.0M8.8M9.3M
202013.3M11.2M9.5M9.7M
201910.8M13.1M14.0M13.0M
201811.4M9.9M9.9M9.7M
201714.0M14.5M13.8M12.8M
201612.7M11.9M12.9M13.6M
201516.2M16.0M15.2M13.9M
201416.3M16.0M16.0M16.2M
201318.3M18.0M17.5M17.2M
201219.9M19.0M18.3M18.3M
201123.3M23.4M21.3M20.2M
2010023.1M23.2M23.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About ThermoGenesis Holdings Inc

THMO
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
 CEO
 WEBSITEthermogenesis.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES40

ThermoGenesis Holdings Inc Frequently Asked Questions

THMO is the stock ticker symbol of ThermoGenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

You can check THMO's fair value in chart for subscribers.

The fair value guage provides a quick view whether THMO is over valued or under valued. Whether ThermoGenesis Holdings Inc is cheap or expensive depends on the assumptions which impact ThermoGenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THMO.

In the past 10 years, ThermoGenesis Holdings Inc has provided -1 (multiply by 100 for percentage) rate of return.